Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 37 (24), 3190-3198

The Role of Immune Correlates of Protection on the Pathway to Licensure, Policy Decision and Use of Group B Streptococcus Vaccines for Maternal Immunization: Considerations From World Health Organization Consultations

Affiliations
Review

The Role of Immune Correlates of Protection on the Pathway to Licensure, Policy Decision and Use of Group B Streptococcus Vaccines for Maternal Immunization: Considerations From World Health Organization Consultations

Johan Vekemans et al. Vaccine.

Abstract

The development of a group B Streptococcus (GBS) vaccine for maternal immunization constitutes a global public health priority, to prevent GBS-associated early life invasive disease, stillbirth, premature birth, maternal sepsis, adverse neurodevelopmental consequences, and to reduce perinatal antibiotic use. Sample size requirements for the conduct of a randomized placebo-controlled trial to assess vaccine efficacy against the most relevant clinical endpoints, under conditions of appropriate ethical standards of care, constitute a significant obstacle on the pathway to vaccine availability. Alternatively, indirect evidence of protection based on immunologic data from vaccine and sero-epidemiological studies, complemented by data from opsonophagocytic in vitro assays and animal models, could be considered as pivotal data for licensure, with subsequent confirmation of effectiveness against disease outcomes in post-licensure evaluations. Based on discussions initiated by the World Health Organization we present key considerations about the potential role of correlates of protection towards an accelerated pathway for GBS vaccine licensure and wide scale use. Priority activities to support progress to regulatory and policy decision are outlined.

Keywords: Correlates of protection; Group B Streptococcus; Maternal immunization; Neonatal sepsis; Vaccines.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Seale A.C., Bianchi-Jassir F., Russell N.J. Estimates of the burden of Group B Streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis. 2017;65(suppl_2):S200–S219. - PMC - PubMed
    1. Russell N.J., Seale A.C., O'Driscoll M. GBS maternal colonization investigator group. maternal colonization with group b streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(suppl_2):S100–S111. - PMC - PubMed
    1. Vekemans J., Moorthy V., Friede M. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine. 2018:31359–31362. - PMC - PubMed
    1. Madrid L., Seale A.C., Kohli-Lynch M. Infant group B Streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65(suppl_2):S160–S172. - PMC - PubMed
    1. Madhi S.A., Cutland C.L., Jose L. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016;16:923–934. - PubMed
Feedback